Table 3.
Medication side effects
| Variable | All patients (n = 2407) | W-ES (n = 1995) | W-Met (n = 358) | M-ES (n = 42) | M-Met (n = 12) | Chi-square p value: M-ES versus W-ES | Chi-square p value: W-ES versus W-Met | Chi-square p value: M-Met versus W-Met |
|---|---|---|---|---|---|---|---|---|
| Reported side effects (%)* | ||||||||
| Any | 2194 (91.2) | 1835 (92.0) | 319 (89.1) | 31 (73.8) | 9 (75.0) | <0.001 | 0.072 | 0.130 |
| Cardiovascular | 309 (12.8) | 262 (13.1) | 41 (11.5) | 3 (7.1) | 3 (25.0) | 0.253 | 0.382 | 0.154 |
| Cognitive/mood | 1515 (62.9) | 1282 (64.3) | 205 (57.3) | 21 (50.0) | 7 (58.3) | 0.057 | 0.011 | 0.941 |
| Eyes | 798 (33.2) | 654 (32.8) | 132 (36.9) | 10 (23.8) | 2 (16.7) | 0.22 | 0.131 | 0.152 |
| General physical changes | 1652 (68.6) | 1381 (69.2) | 248 (69.3) | 17 (40.5) | 6 (50.0) | <0.001 | 0.985 | 0.157 |
| Gastrointestinal | 629 (26.1) | 514 (25.8) | 109 (30.4) | 3 (7.1) | 3 (25.0) | 0.006 | 0.064 | 0.686 |
| Genitourinary | 945 (39.3) | 812 (40.7) | 128 (35.8) | 4 (9.5) | 1 (8.3) | 0.05 | 0.078 | <0.001 |
| Musculoskeletal | 1788 (74.3) | 1488 (74.6) | 278 (77.7) | 15 (35.7) | 7 (58.3) | <0.001 | 0.217 | 0.118 |
| Sexual | 1314 (54.6) | 1087 (54.5) | 199 (55.6) | 21 (50.0) | 7 (58.3) | 0.563 | 0.700 | 0.035 |
| Vasomotor | 1461 (60.7) | 1231 (61.7) | 207 (57.8) | 17 (40.5) | 6 (50.0) | 0.005 | 0.165 | 0.590 |
| High cost of medication | 129 (5.4) | 95 (4.8) | 34 (9.5) | 0 | 0 | 0.148 | <0.001 | 0.263 |
AI aromatase inhibitor, ET endocrine therapy
*Multiple selections permitted
W-ES women, early stage
W-Met women, metastatic
M-ES men, early stage
M-Met men, metastatic